drugset / Trial / NCT00510913

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure

NCT00510913 ↗

Phase 4 Completed 450 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

A study to compare the conversion to Prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure

Timeline

Start
1999-02
Primary completion
—
Completion
2000-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — —

Indications